What is Xact Laboratories?
Xact Laboratories operates at the intersection of clinical pharmacology and digital health, specializing in a patented automated medication safety platform. By integrating pharmacogenomics into the standard prescribing workflow, the company provides real-time genetic insights that serve as a critical clinical decision support tool. Their core offerings, including XactMed4U and XVIS, are engineered to intercept potentially harmful or ineffective drug therapies before they reach the patient. This proactive approach to medication management addresses the systemic challenge of adverse drug reactions, positioning Xact Laboratories as an essential partner for healthcare providers and pharmacies striving to optimize patient outcomes through precision medicine.
How much funding has Xact Laboratories raised?
Xact Laboratories has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Xact Laboratories
PPP
Public-Private Partnership
What's next for Xact Laboratories?
With this late-stage capital, Xact Laboratories is well-positioned to accelerate the deployment of its pharmacogenomic testing solutions. The strategic focus will likely shift toward expanding market penetration within large-scale health systems and pharmacy networks, where the demand for automated safety protocols is increasing. By leveraging this financing, the company aims to enhance its data-driven insights, further refining its clinical decision support algorithms to meet the evolving requirements of personalized medicine. As the healthcare industry continues to prioritize value-based care, Xact Laboratories' ability to reduce medication-related complications provides a clear competitive advantage for long-term growth and operational scalability.
See full Xact Laboratories company page
